SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 30.68+1.7%Jun 5 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bnutman who wrote (52476)9/12/2019 10:36:55 AM
From: Fitzhughlaw4 Recommendations

Recommended By
bnutman
btlbail1
corndog
erippetoe

  Read Replies (1) of 56638
 
It was at the ASCO 2018 presentation given by the company: immunomedics.com. See pages 27-42 ("Sacituzumab Govitecan –Phase 1/2 Results in HR+/HER2–Metastatic Breast Cancer").
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext